{
    "clinical_study": {
        "@rank": "165039", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Determine the safety, feasibility, and potential efficacy of intravascular adenoviral\n      vector mediated gene transfer in the liver in adults with partial ornithine transcarbamylase\n      deficiency."
        }, 
        "brief_title": "Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency", 
        "condition": "Ornithine Transcarbamylase Deficiency Disease", 
        "condition_browse": {
            "mesh_term": [
                "Deficiency Diseases", 
                "Ornithine Carbamoyltransferase Deficiency Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a dose escalation study. Patients undergo a femoral arterial\n      placement of a hepatic intraarterial catheter.  Patients then receive adenoviral vector\n      mediated gene transfer intravascularly over 30 minutes.\n\n      Cohorts of 3 patients each receive escalating doses of adenoviral vector until the maximum\n      tolerated dose is determined.\n\n      Patients are followed at 3, 5, 7, 8, 15, and 29 days, at 2 months, and then every 3 months\n      thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Diagnosis of partial ornithine transcarbamylase deficiency Female heterozygote with\n             abnormal allopurinol challenge or underlying defect in either N15 urea or N15\n             glutamine OR Male with childhood/adulthood onset OR Family history of 2 affected\n             children\n\n          -  Stable for at least 1 month prior to study\n\n          -  Plasma ammonium levels less than 50 micromoles\n\n        --Prior/Concurrent Therapy--\n\n          -  Concurrent alternate pathway therapy to control hyperammonemia allowed\n\n        --Patient Characteristics--\n\n          -  Hepatic: No history of liver disease\n\n          -  Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use\n             effective contraception No high level of neutralizing antibodies to the adenovirus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "69 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "21", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004498", 
            "org_study_id": "199/14290", 
            "secondary_id": "UPSM-FDR001529"
        }, 
        "intervention": {
            "intervention_name": "Adenoviral Vector-Mediated Gene Transfer", 
            "intervention_type": "Genetic"
        }, 
        "keyword": [
            "genetic diseases and dysmorphic syndromes", 
            "inborn errors of metabolism", 
            "ornithine transcarbamylase deficiency", 
            "rare disease", 
            "urea cycle disorder"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "Steven E. Raper", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004498"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "July 1998", 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2000"
    }, 
    "geocoordinates": {}
}